Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients With Recurrent Ovarian Cancer

Next Previous
Trial Profile

A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients With Recurrent Ovarian Cancer

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Olaparib (Primary) ; UV 1 (Primary) ; Sargramostim
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms DOVACC

    • Most Recent Events

    • 16 Apr 2024 According to an Ultimovacs AS media release, the Company implements operational adjustments to support continuous advancement of the UV1 vaccine phase II program. The operational adjustments enable an extension of the financial runway to the fourth quarter of 2025, beyond the anticipated topline readout from this trial.
    • 14 Feb 2024 According to an Ultimovacs AS media release, 75 out of 184 patients have been enrolled to date, up from 46 as of the previous quarterly report. The multinational trial in ten European countries took longer to initiate than anticipated during the pandemic. The readout is expected in H1 2025 (previously guided to H2 2024).
    • 05 Feb 2024 According to an Ultimovacs AS media release, expected readout H2 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top